Search

Puma Biotechnology Inc

Chiusa

SettoreSettore sanitario

9.24 1.43

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

9.02

Massimo

9.18

Metriche Chiave

By Trading Economics

Entrata

12M

8.2M

Vendite

12M

57M

P/E

Media del settore

18.726

56.597

EPS

0.16

Margine di Profitto

14.493

Dipendenti

179

EBITDA

14M

14M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

-34.21% downside

Dividendi

By Acuity

Utili prossimi

5 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

89M

493M

Apertura precedente

7.81

Chiusura precedente

9.24

Notizie sul Sentiment di mercato

By Acuity

50%

50%

112 / 339 Classifica in Healthcare

Puma Biotechnology Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 set 2026, 20:08 UTC

Puma Biotechnology Inc shares are lower today, with no specific news identified. The stock remains below its 20-day moving average.

10 set 2026, 19:46 UTC

Puma Biotechnology Inc shares are higher in Thursday's session, reflecting stability amid fluctuations, though no specific news explains the price movement.

9 set 2026, 19:46 UTC

Puma Biotechnology Inc shares are lower during Wednesday's session, reflecting volatility after a brief gain earlier. No specific news was identified to explain the decline.

8 set 2026, 20:07 UTC

News

Puma Biotechnology Inc shares are lower today, continuing a decline since Friday amid broader market volatility following stronger-than-expected labor market data.

4 set 2026, 20:07 UTC

Puma Biotechnology Inc shares are higher today, reflecting overall market strength, with no specific news identified to explain the movement.

3 set 2026, 20:07 UTC

Puma Biotechnology Inc. shares are lower today, reflecting a decline since Wednesday's close, despite strong performance over the past month.

2 set 2026, 20:08 UTC

Puma Biotechnology shares are higher Wednesday, despite earlier pulling back from a session high. No specific news was identified to explain the movement.

1 set 2026, 20:01 UTC

Puma Biotechnology Inc shares are higher, trading above their 20-day moving average and near the upper end of their one-month range. No specific news was identified.

28 ago 2026, 20:08 UTC

Puma Biotechnology Inc. shares are lower today amid rising U.S. Treasury yields and broader market declines, despite notable intraday volatility.

27 ago 2026, 20:07 UTC

Puma Biotechnology Inc shares are higher, supported by broader market strength and a decline in jobless claims, despite no specific company news.

26 ago 2026, 19:46 UTC

Puma Biotechnology Inc shares are declining today, reaching a session low amid broader market pressures from higher-than-expected consumer prices reported by the Commerce Department.

25 ago 2026, 20:07 UTC

Puma Biotechnology Inc shares are higher, supported by positive market conditions despite a slight pullback from earlier session highs. No specific news was identified.

24 ago 2026, 21:01 UTC

Puma Biotechnology Inc. shares are higher in after-market hours, supported by a rebound in the bond market as Treasury yields decline.

21 ago 2026, 19:51 UTC

Puma Biotechnology shares are higher today, driven by gains in the Biotechnology sub-sector. The stock remains near the upper end of its one-month trading range.

20 ago 2026, 20:06 UTC

Puma Biotechnology Inc shares are lower today, with no specific news identified for the decline. The stock remains above its 20-day moving average.

19 ago 2026, 19:26 UTC

Puma Biotechnology Inc shares are higher since Tuesday's close, maintaining a cumulative return above the 20-day moving average amid no specific news.

18 ago 2026, 20:01 UTC

Puma Biotechnology Inc's shares are higher today, reflecting strong momentum since Monday's close, despite a slight pullback from an earlier session high.

13 ago 2026, 19:26 UTC

Puma Biotechnology Inc shares are lower today, following an early peak. Broader market data showed rising jobless claims and flat producer price index growth.

12 ago 2026, 19:46 UTC

Puma Biotechnology Inc shares are higher today, supported by positive market sentiment following a favorable inflation report. Earlier, shares pulled back from session highs.

11 ago 2026, 22:01 UTC

Puma Biotechnology Inc shares declined in after-market trading, continuing a downward trend since Tuesday's close, amid no specific news to explain the movement.

10 ago 2026, 20:06 UTC

Puma Biotechnology Inc. shares are lower today, reflecting broader market trends amid an unexpected decline in U.S. jobs and inflation reassessments.

7 ago 2026, 20:02 UTC

News

Puma Biotechnology shares rise following strong earnings and TD Cowen's price target increase to $6.00. Trading volume indicates heightened investor interest.

6 ago 2026, 19:26 UTC

Puma Biotechnology Inc shares are higher Thursday, maintaining upward momentum after three consecutive gains, despite a pullback earlier in the session.

5 ago 2026, 21:51 UTC

News

Puma Biotechnology shares are trading lower in after-market hours following the grant of stock awards to new employees, which may dilute existing shareholder value.

4 ago 2026, 19:56 UTC

Puma Biotechnology Inc is trading higher today, benefiting from a decline in crude oil prices that eased inflation concerns. Shares earlier pulled back from a session high.

3 ago 2026, 19:51 UTC

Puma Biotechnology Inc shares are lower today, reflecting a decline since Friday. The stock saw significant volatility, initially rising before dropping sharply.

31 lug 2026, 19:16 UTC

Puma Biotechnology Inc shares are lower today, continuing a decline since Thursday's close. The stock is trading near the lower end of its one-month range.

30 lug 2026, 18:31 UTC

Puma Biotechnology Inc shares are higher as the overall market recovers from recent declines. The stock remains below its 20-day moving average.

29 lug 2026, 18:23 UTC

Puma Biotechnology Inc shares are lower amid broader market weakness as investors await the Federal Reserve's interest rate decision this afternoon.

28 lug 2026, 18:06 UTC

Puma Biotechnology shares are lower amid broader market trends, influenced by declines in Asian markets, particularly in technology sectors.

Confronto tra pari

Modifica del prezzo

Puma Biotechnology Inc Previsione

Obiettivo di Prezzo

By TipRanks

-34.21% in calo

Previsioni per 12 mesi

Media 6 USD  -34.21%

Alto 6 USD

Basso 6 USD

Basato su 1 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Puma Biotechnology Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

1 ratings

0

Acquista

1

Mantieni

0

Vendi

Sentiment

By Acuity

112 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
help-icon Live chat